![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 52, 50230-50236, December 27, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
§¶,
,
¶,
,
¶,
,
,
§§,
¶§§¶¶
From the
Departments of Internal Medicine and
¶¶ Cellular and Molecular Physiology and the ¶ Howard
Hughes Medical Institute, Yale University School of Medicine, New
Haven, Connecticut 06510,
NIDDK, National Institutes of Health,
Bethesda, Maryland 20814, 
Howard
Hughes Medical Institute, Joslin Diabetes Center, Harvard Medical
School, Boston, Massachusetts 02215, and ** Garvan Institute
of Medical Research, Sydney, New South Wales, Australia
Received for publication, January 29, 2002, and in revised form, April 5, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Recent studies have demonstrated that fatty acids
induce insulin resistance in skeletal muscle by blocking insulin
activation of insulin receptor substrate-1 (IRS-1)-associated
phosphatidylinositol 3-kinase (PI3-kinase). To examine the mechanism by
which fatty acids mediate this effect, rats were infused with either a
lipid emulsion (consisting mostly of 18:2 fatty acids) or glycerol. Intracellular C18:2 CoA increased in a time-dependent
fashion, reaching an ~6-fold elevation by 5 h, whereas there was
no change in the concentration of any other fatty acyl-CoAs.
Diacylglycerol (DAG) also increased transiently after 3-4 h of lipid
infusion. In contrast there was no increase in intracellular ceramide
or triglyceride concentrations during the lipid infusion. Increases in
intracellular C18:2 CoA and DAG concentration were associated with
protein kinase C (PKC)- Insulin resistance in skeletal muscle is a major factor in the
pathogenesis of type 2 diabetes. Recent studies in animals and humans
have demonstrated a strong relationship with increased intramuscular
triglyceride content (1-4) and intramyocellular triglyceride content
as assessed by 1H NMR (5-7). In addition, infusions of
lipid emulsions with heparin to acutely raise plasma fatty acid
concentrations have also been shown to cause profound insulin
resistance in rat and human skeletal muscle within 4-6 h (8-11). The
mechanism by which fatty acids induce insulin resistance in skeletal
muscle remains controversial. Randle et al. (12, 13) first
suggested that fatty acids might induce insulin resistance in skeletal
muscle by inhibiting pyruvate dehydrogenase activity, resulting in an
increase in intracellular citrate concentration, which would then
result in inhibition of phosphofructokinase activity leading to an
increase in intracellular glucose-6-phosphate; this in turn would
inhibit hexokinase activity, resulting in decreased glucose uptake.
More recent 31P/13C NMR studies in humans have
revealed a very different mechanism of fatty acid-induced insulin
resistance whereby an increase in plasma fatty acid concentration was
shown to result in lower intramyocellullar glucose 6-phosphate (9, 14)
and glucose concentrations (10), suggesting that fatty acids inhibit
insulin-stimulated glucose transport activity (10). These changes were
associated with reduced insulin-stimulated
IRS-11 tyrosine
phosphorylation (11) and IRS-1-associated phosphatidylinositol 3-kinase
(PI3-kinase) activity (10, 11) suggesting that fatty acids cause
insulin resistance through inhibition of insulin signaling, which we
hypothesized might occur through activation of a serine kinase cascade
involving PKC- Materials--
LCACoA standards (C16:1, C16:0, C17:0, C18:2,
C18:1, and C18:0), diacylglyceride standards, and ceramide standards
(C6:0, C16:0, C18:0) were purchased from Sigma.
N-Arachidoyl-D-sphingosine and
N-lignoceroyl-D-sphingosine were
purchased from Avanti Polar Lipids (Arlington, AL). Antibody against
IRS-1 was purchased from Upstate Biotechnology (Lake Placid, NY).
Antibody against the insulin receptor subunit and
Zymed phosphotyrosine and rabbit anti-peptide against
nPKC- Animals--
Male Wistar rats (Charles River, Wilmington, MA)
weighing between 250 and 300 g (for the time course study) and 50 and 75 g (for insulin dose response) were housed in an
environmentally controlled room with a 12-h light/dark cycle and fed
with regular rat chow diet. The rats were catheterized in the right
jugular vein and carotid artery; the catheters were externalized
through an incision in the skin flap behind their head. The rats were allowed to recover from surgery until they reached preoperative weight
(~5-7 days) and were fasted overnight (~15 h) before the infusion
experiment. All procedures were approved by the Yale University Animal
Care and Use Committee.
Intralipid Time Course Studies--
The rats were divided
randomly into five study groups (6-8 rats/group). The control group
was infused with isotonic saline solution for 5 h. The other
groups were infused with a 20% triglycerides emulsion (Liposyn II,
Abbott Laboratories, North Chicago, IL) (5 ml/kg/h) combined with
heparin (6 units/h) for 1, 3 and 5 h. A fifth wash-out group was
infused with lipid/heparin for 5 h, which was then discontinued
and followed with an isotonic saline infusion for another 3 h.
Identical studies were performed for muscle DAG analysis (3-9
rats/group) with the addition of a 4-h lipid/heparin infusion group
(n = 4). At the end of the infusions, rats were
anesthetized with pentobarbital (50 mg/kg); soleus muscle samples,
rapidly dissected and freeze-clamped in situ, were stored at
Extraction of LCACoAs, DAGs, and Ceramides from Tissue
Samples--
LCACoAs were extracted from frozen tissue samples (~100
mg) and purified using a solid phase extraction method described
previously by Deutsch et al. (15) with minor modifications
for desalting. A known amount of heptadecanoyl-CoA was added as an
internal standard. OPC columns (Applied Biosystems, Foster City,
CA) were used for solid phase extraction. Samples were dissolved in 100 µl of methanol/H2O for LC/MS/MS analysis.
DAGs and ceramides were extracted from frozen tissue (~100 mg) with
chloroform/methanol (2:1, v/v) containing 0.01% butylated hydroxytoluene. Prior to the extraction, known amounts of
1,3-dipentadecanoin, triheptadecanoin, and hexanoylsphingosine were
added as internal standards. Extracted samples were evaporated to
dryness and redissolved in 1 ml of hexane-methylene chloride-ethyl
ether (95:5:0.5, v/v/v). DAGs were isolated from triglycerides by use
of a diol bonded-phase SPE column (Waters, Inc., Milford, MA)
under vacuum, as described previously (16). Briefly, the SPE column was
preconditioned with 4 ml of hexane. The lipid extract was then placed
on the column, and triglycerides were eluted with 8 ml of
hexane-methylene chloride-ethyl ether (89:10:1, v/v/v). DAGs were
eluted with 8 ml of hexane-ethyl acetate (85:15, v/v) into a second set
of collection tubes. The solvent was evaporated to dryness under vacuum
and redissolved in 0.5 ml of hexane-ethyl acetate (85:15, v/v) for LC/MS/MS analysis. Monitoring for the presence of triheptadecanoin in
the DAG fraction assessed the separation of triglycerides from DAGs.
LC/MS/MS Analysis of LCACoAs, DAGs, and
Ceramides--
A bench-top tandem mass spectrometer, API 3000 (PerkinElmer Life Sciences), interfaced with a TurboIonspray ionization
source or atmospheric pressure chemical ionization source was used.
Peripherals included a PerkinElmer series 200 micro-pump and an
autosampler. LCACoAs were ionized in negative electrospray mode. Doubly
charged ions and corresponding product ions were chosen as transition pairs for each CoA species (C16:1, C16:0, C18:2, C18:1, and C18:0) for
selective reactions monitoring (SRM) quantitation. Total LCACoAs contents were obtained from the sum of individual species.
Methanol/H2O (60/40) was used as continuous flow at 300 µl/min, and 5 µl of sample was injected for analysis. DAGs (derived
from C16:1, C16:0, C18:2, C18:1, and C18:0) and ceramides (C16:0,
C18:0, C20:0, C22:0, C24:1, C24:0) were ionized in positive atmospheric
pressure chemical ionization mode. [M+H-18]+/product ions
from corresponding fatty acid moiety were monitored for SRM
quantitation for DAGs. [M+H-18]+/264.3 were monitored for
ceramide species for quantitation. The same mobile phase was used for
LCACoAs at 300 µl/min with 3 µl of sample injected.
In Vitro Muscle Studies--
After a 5-h infusion with glycerol
(as control) or lipid/heparin at 85 µl/kg/min, rats were anesthetized
with an intravenous injection of sodium pentobarbital (50 mg/kg).
Soleus muscles were isolated from the rats and preincubated in
oxygenated (95% O2, 5% CO2) Krebs-Henseleit
bicarbonated (KHB) buffer containing 2 mM pyruvate, 36 mM mannitol, and 0.1% bovine serum albumin (preincubation buffer) to recover for 30 min at 18 °C. The soleus muscles were then
incubated at 29 °C in oxygenated preincubation buffer with various
concentration of insulin (0, 50, 1,000, or 10,000 microunits/ml) for 35 min. After incubation, the muscles were rinsed with ice-cold saline and
freeze-clamped in liquid nitrogen for analysis of insulin-stimulated IRS-1 tyrosine phosphorylation and insulin-stimulated IRS-1-associated PI3-kinase activity. To measure the insulin-stimulated glucose uptake
in the muscle, soleus muscles were preincubated at 29 °C with
various concentrations of insulin (0, 50, 1,000, or 10,000 microunits/ml) for 35 min followed by incubation in KHB buffer containing 1 mM [3H]2-deoxyglucose and
39 mM [1-14C]mannitol for an additional 20 min. For IRS-1 serine phosphorylation analysis, after a 5-h lipid
infusion, soleus muscles were freeze-clamped in situ and
kept in liquid nitrogen until analysis.
Insulin Signaling Assays--
Muscle samples were ground under
liquid nitrogen and homogenized in a ice-cold Hepes buffer, pH 7.4, containing 150 mM NaCl 50 mM IR and IRS-1 Tyrosine Phosphorylation
Assays--
Immunoprecipitates were washed three times by brief
centrifugation and gentle resuspension in ice-cold homogenization
buffer plus 0.1% SDS. Immunoprecipitates were subjected to SDS-PAGE on a 4-12% gradient gel. Proteins were transferred to nitrocellulose membrane using a semidry electro-blotter (Owl Separation System, Portsmouth, NH). The membranes were immunoblotted with
anti-phosphotyrosine antibody, and bands were visualized using enhanced
chemiluminescence (Amersham Biosciences) and quantified by densitometry
(Amersham Biosciences). The membrane was stripped with 100 mM glycine, pH 3.0, and reblotted with anti-IRS-1 antibody
to determine the amount of IRS-1 proteins.
IRS-1 serine phosphorylation was measured using a site-specific
antibody, phospho-Ser307, generated in Dr. Morris White's
laboratory (17). Immunoprecipitation and Western blotting procedures
were the same as for IRS-1 tyrosine phosphorylation.
PI3-kinase Activity Assay--
The immunoprecipitates were
washed twice with phosphate-buffered saline, twice with 100 mM Tris, pH 7.5, containing 500 mM LiCl2, and twice with 10 mM Tris containing 150 mM NaCl and 1 mM EDTA. 100 µM
Na3VO4 was included in all the wash buffers.
Kinase reactions were done as described previously (11).
32P was captured with a storage phosphor-screen, and the
screen was scanned with a Storm system. Images were analyzed and
quantified using ImageQuant software.
PKC- Analytical Procedures--
Plasma fatty acid concentration was
determined with an acyl-CoA oxidase-based colorimetric kit (Wako
NEFA-C, Wako Pure Chemicals, Osaka, Japan). Tissue triglycerides
were extracted by adapting the method described by Storlien et
al. (19), and triglyceride content was measured using a kit from Sigma.
Statistical Analysis--
Data were expressed as means ± S.E. Analysis of data using analysis-of-variance with one-way post-hoc
tests (Fisher's protected least significant difference) was done to
determine the differences between control and different time
courses of lipid infusion groups at a minimum p < 0.05 threshold.
Basal plasma fatty concentration increased rapidly following the
lipid/heparin infusion and remained constant until the saline wash-out
period during which time it returned to base-line concentration (Fig.
1A). This increase in plasma
fatty acid concentration in the lipid-infused group resulted in
increases in both intramuscular LCACoAs and DAG concentration in the
soleus muscle compared with the control group (Fig. 1, B and
C). Although the LCACoA continued to increase throughout the
lipid infusion, the DAGs reached a peak concentration at 3-4 h and
then surprisingly decreased to basal concentrations despite continued
lipid infusion (Fig. 1C). In contrast, lipid infusion had no
effect on intramyocellullar ceramide content (Fig. 1D) or
muscle triglyceride (Fig. 1E) content except at the
1-h time point, at which time the concentration decreased
compared with base line. The increase in total LCACoA concentration
could be accounted for entirely by a selective increase in C18:2 CoA
(major fatty acid composition in liposyn II) (3.86 ± 0.46 nmol/g
of weight for control group, 9.30* ± 0.87, 16.17** ± 2.37, and
18.89** ± 2.51 nmol/g of weight after a 1-h, 3-h, and 5-h lipid
infusion and 7.22 ± 1.22 nmol/g of weight after wash-out period;
*, p < 0.05 versus control; **,
p < 0.001 versus control; Fig.
2A). In contrast the transient
~3-4-fold increase in total DAG content at 3-4 h (0.65 ± 0.14 µmol/g of weight for control group, 1.43 ± 0.51, 2.73 ± 0.83+, 2.54 ± 0.79+, 1.36 ± 0.40, 0.96 ± 0.31 µmol/g of weight for 1-h, 3-h, 4-h, 5-h and
wash-out groups, respectively; +, p
activation and a reduction in both insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1 associated PI3-kinase activity, which were associated with an increase in IRS-1
Ser307 phosphorylation. These data support the
hypothesis that an increase in plasma fatty acid concentration results
in an increase in intracellular fatty acyl-CoA and DAG concentrations,
which results in activation of PKC-
leading to increased IRS-1
Ser307 phosphorylation. This in turn leads to
decreased IRS-1 tyrosine phosphorylation and decreased activation of
IRS-1-associated PI3-kinase activity resulting in decreased
insulin-stimulated glucose transport activity.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(11). To explore the possible roles of different
intracellular fatty acid metabolites such as fatty acyl-CoA,
diacylglycerol (DAG), ceramides, and triglycerides in mediating fatty
acid-induced insulin resistance in skeletal muscle, we measured these
metabolites at different time intervals during a lipid infusion in
relation to insulin stimulation: (i) insulin receptor tyrosine
phosphorylation, (ii) IRS-1 tyrosine phosphorylation, and (iii)
IRS-1-associated PI3-kinase activity as well as PKC-
translocation.
In a separate group of in vitro soleus muscle studies, we
also examined whether fatty acid-induced defects in insulin signaling
were coupled to defects in insulin-stimulated glucose uptake across a
range of insulin concentrations.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
were from Santa Cruz Biotechnology (Santa Cruz, CA).
Goat anti-mouse IgG antibodies conjugated to horseradish peroxidase
were obtained from Caltag Laboratories (Burlingame, CA). Mouse
monoclonal antibody against PKC-
was from Transduction Laboratories
(Lexington, KY).
70 °C for measurement of fat metabolites. Soleus muscle was selected for all studies because it consists of mostly type 1 fiber,
which is highly insulin-responsive and best reflects insulin action in
human skeletal muscle (10, 11). To study the effect of fatty acids on
insulin signaling in muscle at the same time points, we performed
another set of identical parallel studies in five groups (basal, 1, 3, an 5 h lipid/heparin infusion and 3 h wash-out) under
conditions identical to those described above, adding a 20-min
hyperinsulinemic euglycemic clamp following the lipid/heparin or saline
infusion. In these studies an intravenous bolus (150 milliunits/kg for
45 s, 75 milliunits/kg for another 45 s) of insulin (humulin
regular insulin, Eli Lily, Indianapolis, IN) was followed by a constant
insulin infusion at 10 milliunits/kg/min, with plasma glucose
concentration clamped at 5.5 mM using a variable infusion
of glucose (50g/dl) to maintain euglycemia as described previously
(11). At the end of the clamps, rats were anesthetized with
pentobarbital (50 mg/kg). Soleus muscle samples were rapidly dissected,
freeze-clamped in situ, and stored at
70 °C for insulin signaling assays. Rats were euthanized with a lethal dose of pentobarbital.
-glycerol
phosphate, 2 mM dithiothreitol, 1 mM
NaVO4, 2 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 1% Triton-100, 10% glycerol, and 10 µg/ml aprotinin. The homogenates were centrifuged at
20,500 × g for 1 h. Supernatants were collected,
and protein concentration was measured with the Bradford protein assay
reagent (Bio-Rad). Muscle homogenates (4 mg protein) were
immunoprecipitated with 4 µg of anti-IRS-1 antibody for 18 h for
IRS-1 tyrosine phosphorylation and PI3-kinase activity assay or with 4 µg of anti-IR antibody for IR tyrosine phosphorylation.
Translocation Assay--
100 mg of soleus muscle was
homogenized and extracted in 4× (w/v) ice cold 20 mM MOPS, pH 7.5, 250 mM mannitol, 1.2 mM EGTA, 1 mM dithiothreitol, 2 mM
phenylmethylsulfonyl fluoride, leupeptin (200 µg/ml), and 2 mM benzamidine. The homogenate was solubilized by hand for
2 min and centrifuged at 4 °C for 10 min at 100,000 × g. Separation of cytosol and membrane fraction was done as
described previously (18). 5 (cytosolic) or 10 µg (particulate) of
protein was loaded and subjected to SDS-PAGE (10% gel, 187 V).
Proteins separated on the gels were electrophoretically transferred to polyvinylidene difluoride filter membranes (Amersham Biosciences) in 19 mM Tris, pH 8.9, buffer containing 140 mM
glycine at 90 V for 90 min. Polyvinylidene difluoride membranes were
probed with 0.625 µg/ml anti-PKC-
antibody (Transduction
Laboratories) for 2 h at room temperature, followed by horseradish
peroxidase-conjugated goat anti-mouse antibody (1:5,000) for 2 h.
PKC isozymes visualized by enhanced chemiluminescence reagents and
quantitated by densitometry using a Medical Dynamics Personal
Densitometer SI and IP Lab Gel H software (Signal Analytics, Vienna,
VA). Individual band densities were adjusted for inter-gel variability
using the standard, and the amount of PKC
in each fraction were
calculated according to the total amount of protein in the final volume
of supernatant extracted.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
0.006 versus control) could be attributed to an increase in
virtually all DAG species (Fig. 2B). These increases in
intracellular LCACoA and DAG concentrations were associated with
PKC-
activation, as reflected by a significant reduction in the
fraction of PKC-
in the cytosol and a significant increase in the
PKC-
membrane-associated/cytosol fraction after 5 h of lipid
infusion (both p = 0.04 versus control
group; Fig. 3). There was also a
reduction in total PKC-
content, which is consistent with previous
observations in a high-fat fed rat model that had increased
intramuscular lipid accumulation (20).

View larger version (18K):
[in a new window]
Fig. 1.
Time course for plasma fatty acid and
intracellular fat metabolite concentrations in soleus muscles during
lipid infusion. A, plasma fatty acid concentrations;
B, LCACoA concentrations; C, diacylglyceride
concentrations; D, ceramide concentrations; E,
triglyceride concentrations. Values are means ± S.E. for
6-10 experiments. *, p < 0.05 versus
control groups; +, p
0.006, and **,
p < 0.001 versus base line.

View larger version (32K):
[in a new window]
Fig. 2.
Time course for the concentration profiles of
LCACoAs and DAG in soleus muscles during the lipid infusion.
A, individual LCACoAs species were quantitated:
C16:1, palmitoleoyl-CoA; C16:0, palmitoyl-CoA;
C18:2, linoleoyl-CoA; C18:1, oleoyl-CoA; and
C18:0, stearoyl-CoA. Values are means ± S.E. for 6-10
experiments. *, p < 0.05 versus control
group; **, p < 0.001 versus control group.
B, DAG species were abbreviated as two contributing fatty
acyl groups. S, stearoyl; O, oleoyl;
L, linoleoyl; P, palmitoyl; Po,
palmitoleoyl. Values are means ± S.E. for 3-9 experiments. *,
p < 0.05 versus control group.

View larger version (23K):
[in a new window]
Fig. 3.
Time course for the effects of fatty acids on
PKC-
activity in soleus muscle in
vivo. PKC-
protein levels were determined in the
cytosolic and membrane fraction by immunoblotting with PKC-
specific
antibodies. Total PKC-
levels were calculated from the sum of
cytosolic and membrane-associated amounts, and PKC-
distribution was
expressed as the ratio of membrane-associated to cytosolic amounts.
W/O, without. Values are means ± S.E. for 6-10
experiments. *, p < 0.05 versus control
groups.
The increase in intracellular fatty acyl-CoA and PKC-
activation
were also associated with a significant impairment in
insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1-associated
PI3-kinase activity after 5 h of lipid infusion (Fig.
4). These changes were associated with a
1.6-fold increase (p = 0.002 versus control) in IRS-1 Ser307 phosphorylation following 5 h of lipid
infusion (Fig. 5). In contrast lipid
infusion did not inhibit insulin-stimulated insulin receptor
tyrosine phosphorylation (Fig. 4).
|
|
Following the 3-h lipid wash-out period, intracellular 18:2 acyl-CoA
returned to base-line concentrations, and PKC-
activity returned to
normal (Figs. 1 and 3). In parallel with these results insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1-associated PI3-kinase activity also returned to normal.
To determine whether higher concentrations of insulin could overcome
these lipid-induced defects in insulin signaling and action, we also
examined insulin-stimulated muscle glucose uptake and insulin signaling
across a wide range of insulin concentrations (50, 1,000, and 10,000 microunits/ml) in an in vitro soleus muscle preparation
following 5 h of either lipid or glycerol infusion. Consistent
with our previous results, 5 h of lipid infusion induced a
profound defect in insulin-stimulated glucose uptake, which occurred
across all insulin concentrations (Fig.
6). This reduction in insulin-stimulated
glucose uptake was paralleled by similar reductions in
insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1-associated
PI3-kinase activity across all insulin concentrations, but there was no
change in insulin receptor tyrosine phosphorylation (Fig.
7). Taken together these results
demonstrates that fatty acids induce a defect in insulin activation of
PI3-kinase at the level of IRS-1 tyrosine phosphorylation that cannot
be overcome with supraphysiologic concentrations of insulin.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
To examine the possible roles of fatty acyl-CoA, diacylglycerol,
ceramides, and triglycerides in mediating fatty acid induced insulin
resistance in skeletal muscle, we assessed the intracellular concentration of these metabolites at different time intervals during a
lipid infusion in awake rats. The changes in these fatty acid
metabolite concentrations were then compared with changes in
insulin-stimulated insulin receptor tyrosine phosphorylation, IRS-1
tyrosine phosphorylation, IRS-1-associated PI3-kinase activity, and
PKC-
translocation. We found that during the lipid infusion intra- myocellullar C18:2 CoA concentration increased by ~6-fold and that it was the only intracellular fatty acyl-CoA to increase. Because the infused intralipid consisted mostly of C18:2 fatty acids,
these data strongly suggest that this intracellular fatty acyl-CoA was
derived from the infused lipid. Following the increase in intracellular
C18:2 CoA, there was a ~3-fold increase in intracellular DAG, which
peaked at 3-4 h and then surprisingly declined despite persistent
elevation in plasma fatty acid concentrations. In contrast to the fatty
acyl-CoA, which consisted mostly of C18:2 fatty acids, the increase in
DAG consisted of virtually all measured fatty acids. Taken together
these data suggest that an increase in intracellular fatty acyl-CoA
activates a phospholipase that leads to production of DAG from
endogenous lipid sources, which might explain the observed decrease in
intramuscular triglyceride content during the first couple of hours of
the lipid infusion. In contrast to the increases in intracellular fatty
acyl-CoA and DAG, there were no significant increases in intracellular
ceramides or triglyceride concentrations during the 5-h lipid infusion,
which suggests that these metabolites do not play a major role in
mediating fatty acid-induced insulin resistance in skeletal muscle.
In parallel with the increases in intracellular fatty acyl-CoA, we
observed a ~30% reduction in insulin activation of IRS-1 tyrosine
phosphorylation and an ~50% reduction in IRS-1-associated PI3-kinase
activity after 5 h of lipid infusion, which coincided with
activation of PKC-
. These data might explain the 3-5 h delay for
fatty acid-induced insulin resistance in skeletal muscle resulting from
an intralipid/heparin infusion (8, 9). In contrast, the lipid infusion
had no effect on insulin receptor tyrosine phosphorylation. Overall
these data demonstrate that increases in plasma fatty acid
concentration inhibit insulin activation of IRS-1-associated PI3-kinase
at the level of IRS-1, possibly though activation of PKC-
, a known
serine kinase. To gain further insights into this mechanism we assessed
IRS-1 Ser307 phosphorylation. Previous in vitro
studies by Aguirre et al. (17) demonstrated that
IRS-1 Ser307 phosphorylation is a critical site in
mediating TNF
-induced insulin resistance in Chinese hamster ovary
cells. When IRS-1 Ser307 was mutated to IRS-1
Ala307, these cells were protected from TNF
-induced
insulin resistance. Indeed, in the present study we found that after
5 h of lipid infusion there was a 1.6-fold increase in IRS-1
Ser307 phosphorylation in soleus muscle, which suggests
that fatty acids may mediate insulin resistance through the same common
final pathway as TNF
(21).
To determine whether higher concentrations of insulin could overcome these fatty acid-induced defects in insulin signaling and action, we also examined these parameters in vitro, across a wide range of insulin concentrations, in soleus muscles obtained from rats following 5 h of either lipid or glycerol infusion. Consistent with our current and previous in vivo results, 5 h of lipid infusion induced a profound defect in insulin-stimulated glucose uptake (9-11), which occurred across all insulin concentrations. This reduction in insulin-stimulated glucose uptake was paralleled by similar reductions in insulin-stimulated IRS-1 tyrosine phosphorylation and IRS-1-associated PI3-kinase activity across all insulin concentrations, but there was no change in insulin-stimulated IR tyrosine phosphorylation. Taken together these results demonstrate that the fatty acid-induced inhibition of insulin-stimulated glucose transport activity in muscle can be explained for the most part by decreased activation of PI3-kinase at the level of IRS-1 tyrosine phosphorylation, which cannot be overcome with supraphysiologic concentrations of insulin.
In conclusion, these data provide new insights into the pathogenesis of
fat-induced insulin resistance in skeletal muscle and support the
hypothesis that an increase in plasma fatty acid concentration results
in an increase in intracellular fatty acyl-CoA and DAG concentrations,
which then results in activation of PKC-
leading to increased IRS-1
Ser307 phosphorylation. These changes in turn result in
decreased IRS-1 tyrosine phosphorylation and decreased activation of
IRS-1-associated PI3-kinase, resulting in decreased insulin-stimulated
glucose transport activity.
| |
ACKNOWLEDGEMENTS |
|---|
We acknowledge the expert technical assistance of Hyegeong Kim, Lynn Croft, Anthony Romanelli, Taca Higashimori, and Theresa Choi.
| |
FOOTNOTES |
|---|
* This work was supported by Grants R01 DK-40936 and P30 DK-45735 from the National Institutes of Health and a Center grant to the Garvan Institute from the National Health and Medical Research Council of Australia.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Contributed equally to this work.
§§ Investigators of the Howard Hughes Medical Institute.

To whom correspondence should be addressed: Howard
Hughes Medical Institute, Yale University School of Medicine, Boyer
Center for Molecular Medicine, 295 Congress Ave., BCMM 254, Box 9812, New Haven, CT 06536-0812. Tel.: 203-785-5447; Fax: 203-737-4059; E-mail: gerald.shulman@yale.edu.
Published, JBC Papers in Press, November 14, 2002, DOI 10.1074/jbc.M200958200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
IRS-1, insulin
receptor substrate-1;
IR, insulin receptor;
PI3-kinase, phosphatidylinositol 3-kinase;
PKC, protein kinase C;
DAG, diacylglycerol;
LCACoA, long-chain acyl-CoA;
LC/MS/MS, liquid
chromatography tandem mass spectrometry;
MOPS, 4-morpholinepropanesulfonic acid;
TNF
, tumor necrosis factor
.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Kraegen, E. W., Cooney, G. J., Ye, J. M., Thompson, A. L., and Furler, S. M. (2001) Exp. Clin. Endocrinol. Diabetes 109 Suppl 2, S189-S201 |
| 2. |
Kim, J. K.,
Gavrilova, O.,
Chen, Y.,
Reitman, M. L.,
and Shulman, G. I.
(2000)
J. Biol. Chem.
275,
8456-8460 |
| 3. |
Kim, J. K.,
Fillmore, J. J.,
Chen, Y., Yu, C.,
Moore, I. K.,
Pypaert, M.,
Lutz, E. P.,
Kako, Y.,
Velez-Carrasco, W.,
Goldberg, I. J.,
Breslow, J. L.,
and Shulman, G. I.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
7522-7527 |
| 4. | Pan, D., Lillioja, S., Kriketos, A., Milner, M., Baur, L., Bogardus, C., Jenkins, A., and Storlien, L. (1997) Diabetes 46, 983-988[Abstract] |
| 5. | Krssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Roden, M., and Shulman, G. I. (1999) Diabetologia 42, 113-116[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Perseghin, G., Scifo, P., De, Cobelli, F., Pagliato, E., Battezzati, A., Arcelloni, C., Vanzulli, A., Testolin, G., Pozza, G., Del Maschio, A., and Luzi, L. (1999) Diabetes 48, 1600-1606[Abstract] |
| 7. | Jacob, S., Machann, J., Rett, K., Bretchel, K., Volk, A., Renn, W., Maerker, E., Matthaei, S., Schick, F., Claussen, C. D., and Harring, H. U. (1999) Diabetes 48, 1113-1119[Abstract] |
| 8. | Boden, G., and Chen, X. (1995) J. Clin. Invest. 96, 1261-1268[Medline] [Order article via Infotrieve] |
| 9. | Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., and Shulman, G. I. (1996) J. Clin. Invest. 97, 2859-2865[Medline] [Order article via Infotrieve] |
| 10. | Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., Petersen, K. F., and Shulman, G. I. (1999) J. Clin. Invest. 103, 253-259[Medline] [Order article via Infotrieve] |
| 11. | Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., and Shulman, G. I. (1999) Diabetes 48, 1270-1274[Abstract] |
| 12. | Randle, P. J., Garland, P. B., Hales, C. N., and Newsholme, E. A. (1963) Lancet i, 785-789 |
| 13. | Randle, P. J., Newsholme, E. A., and Garland, P. B. (1964) Biochem. J. 93, 652-665[Medline] [Order article via Infotrieve] |
| 14. | Roden, M., Krssak, M., Stingl, H., Gruber, S., Hofer, A., Furnsinn, C., Moser, E., and Waldhausl, W. (1999) Diabetes 48, 358-364[Abstract] |
| 15. | Deutsch, J., Grange, E., Rapoport, S. I., and Purdon, A. D. (1994) Anal. Biochem. 220, 321-323[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Pacheco, Y. M., Perez-Camino, M. C., Cert, A., Montero, E., and Ruiz-Gutierrez, V. (1998) J. Chromatogr. B Biomed. Sci. Appl. 714, 127-132[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Aguirre, V.,
Uchida, T.,
Yenush, L.,
Davis, R.,
and White, M.
(2000)
J. Biol. Chem.
275,
9047-9054 |
| 18. |
Laybutt, D. R.,
Schmitz-Peiffer, C.,
Saha, A. K.,
Ruderman, N. B.,
Biden, T. J.,
and Kraegen, E. W.
(1999)
Am. J. Physiol.
277,
E1070-E1076 |
| 19. | Storlien, L. H., Jenkins, A. B., Chisholm, D. J., Pascoe, W. S., Khouri, S., and Kraegen, E. W. (1991) Diabetes 40, 280-289[Abstract] |
| 20. | Schmitz-Peiffer, C., Browne, C. L., Oakes, N. D., Watkinson, A., Chisholm, D. J., Kraegen, E. W., and Biden, T. J. (1997) Diabetes 46, 169-178[Abstract] |
| 21. | Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., and Spiegelman, B. M. (1996) Science 271, 665-668[Abstract] |
This article has been cited by other articles:
![]() |
M. Adiels, S.-O. Olofsson, M.-R. Taskinen, and J. Boren Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1225 - 1236. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schmitz-Peiffer and T. J. Biden Protein Kinase C Function in Muscle, Liver, and {beta}-Cells and Its Therapeutic Implications for Type 2 Diabetes Diabetes, July 1, 2008; 57(7): 1774 - 1783. [Full Text] [PDF] |
||||
![]() |
A. Bakhai Adipokines--targeting a root cause of cardiometabolic risk QJM, June 10, 2008; (2008) hcn066v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Puri, S. Ranjit, S. Konda, S. M. C. Nicoloro, J. Straubhaar, A. Chawla, M. Chouinard, C. Lin, A. Burkart, S. Corvera, et al. Cidea is associated with lipid droplets and insulin sensitivity in humans PNAS, June 3, 2008; 105(22): 7833 - 7838. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Freda, W. Shen, S. B. Heymsfield, C. M. Reyes-Vidal, E. B. Geer, J. N. Bruce, and D. Gallagher Lower Visceral and Subcutaneous but Higher Intermuscular Adipose Tissue Depots in Patients with Growth Hormone and Insulin-Like Growth Factor I Excess Due to Acromegaly J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2334 - 2343. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Frangioudakis and G. J Cooney Acute elevation of circulating fatty acids impairs downstream insulin signalling in rat skeletal muscle in vivo independent of effects on stress signalling J. Endocrinol., May 1, 2008; 197(2): 277 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Watt, B. J. W. van Denderen, L. A. Castelli, C. R. Bruce, A. J. Hoy, E. W. Kraegen, L. Macaulay, and B. E. Kemp Adipose Triglyceride Lipase Regulation of Skeletal Muscle Lipid Metabolism and Insulin Responsiveness Mol. Endocrinol., May 1, 2008; 22(5): 1200 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, H. T. Kim, Y. Ma, L. Zhao, L. Zhai, N. Kokorina, P. Wang, and J. L. Messina Trauma and Hemorrhage-Induced Acute Hepatic Insulin Resistance: Dominant Role of Tumor Necrosis Factor-{alpha} Endocrinology, May 1, 2008; 149(5): 2369 - 2382. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Dube, F. Amati, M. Stefanovic-Racic, F. G. S. Toledo, S. E. Sauers, and B. H. Goodpaster Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E882 - E888. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Waraich, C. Weigert, H. Kalbacher, A. M. Hennige, S. Z. Lutz, H.-U. Haring, E. D. Schleicher, W. Voelter, and R. Lehmann Phosphorylation of Ser357 of Rat Insulin Receptor Substrate-1 Mediates Adverse Effects of Protein Kinase C-{delta} on Insulin Action in Skeletal Muscle Cells J. Biol. Chem., April 25, 2008; 283(17): 11226 - 11233. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Thyfault Setting the stage: possible mechanisms by which acute contraction restores insulin sensitivity in muscle Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1103 - R1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Thrush, G. J. Heigenhauser, K. L. Mullen, D. C. Wright, and D. J. Dyck Palmitate acutely induces insulin resistance in isolated muscle from obese but not lean humans Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1205 - R1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C Venables, C. J Hulston, H. R Cox, and A. E Jeukendrup Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans Am. J. Clinical Nutrition, March 1, 2008; 87(3): 778 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Civitarese and E. Ravussin Minireview: Mitochondrial Energetics and Insulin Resistance Endocrinology, March 1, 2008; 149(3): 950 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Bakker, P. Sipkema, C. D.A. Stehouwer, E. H. Serne, Y. M. Smulders, V. W.M. van Hinsbergh, and E. C. Eringa Protein Kinase C {theta} Activation Induces Insulin-Mediated Constriction of Muscle Resistance Arteries Diabetes, March 1, 2008; 57(3): 706 - 713. [Abstract] [Full Text] [PDF] |
||||